Agile Therapeutics, Inc. to Report on Development Status of New Generation Low- Estrogen Dose Contraceptive Patch at Biotechnology Industry Organization (BIO) 2007 Conference

PRINCETON, N.J., April 23 /PRNewswire/ -- Dr. Thomas M. Rossi, President and Chief Executive Officer of Agile Therapeutics, Inc., will report on the company's progress in developing a new generation of transdermal contraceptives at the BIO 2007 annual international conference on biotechnology. Agile is an early stage Women's Healthcare company, whose low estrogen dose, seven-day transdermal contraceptive patch is currently in phase 2 clinical development.

The BIO 2007 conference will be held at the Boston Convention and Exhibition Center in Boston, MA on May 6 - May 9th, 2007. Dr. Rossi is scheduled to present at 9:30 am in Room C.

Agile Therapeutics is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.

About Agile Therapeutics

Agile Therapeutics, Inc. is a pharmaceutical product development company founded in 1997 based on developing novel pharmaceutical products utilizing its proprietary transdermal drug delivery technology. For more information, log on to www.agiletherapeutics.com.

Agile Therapeutics, Inc.

CONTACT: Steve Ross, +1-908-507-7335

MORE ON THIS TOPIC